Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.
Superinvestors holding ELVN, Q2 2026
No superinvestor reported holding ELVN in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ELVN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2025
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q3 2025
1 superinvestor holding at quarter end
- Added
- Duquesne Family Office (+104.6%)
Q2 2025
1 superinvestor holding at quarter end